1. Home
  2. QNCX vs IMUX Comparison

QNCX vs IMUX Comparison

Compare QNCX & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QNCX
  • IMUX
  • Stock Information
  • Founded
  • QNCX 2012
  • IMUX 2016
  • Country
  • QNCX United States
  • IMUX United States
  • Employees
  • QNCX N/A
  • IMUX N/A
  • Industry
  • QNCX Biotechnology: Biological Products (No Diagnostic Substances)
  • IMUX Biotechnology: Pharmaceutical Preparations
  • Sector
  • QNCX Health Care
  • IMUX Health Care
  • Exchange
  • QNCX Nasdaq
  • IMUX Nasdaq
  • Market Cap
  • QNCX 62.0M
  • IMUX 86.3M
  • IPO Year
  • QNCX 2019
  • IMUX N/A
  • Fundamental
  • Price
  • QNCX $1.40
  • IMUX $1.00
  • Analyst Decision
  • QNCX Strong Buy
  • IMUX Strong Buy
  • Analyst Count
  • QNCX 4
  • IMUX 6
  • Target Price
  • QNCX $9.50
  • IMUX $12.67
  • AVG Volume (30 Days)
  • QNCX 126.6K
  • IMUX 923.9K
  • Earning Date
  • QNCX 03-31-2025
  • IMUX 02-24-2025
  • Dividend Yield
  • QNCX N/A
  • IMUX N/A
  • EPS Growth
  • QNCX N/A
  • IMUX N/A
  • EPS
  • QNCX N/A
  • IMUX N/A
  • Revenue
  • QNCX N/A
  • IMUX N/A
  • Revenue This Year
  • QNCX N/A
  • IMUX N/A
  • Revenue Next Year
  • QNCX N/A
  • IMUX N/A
  • P/E Ratio
  • QNCX N/A
  • IMUX N/A
  • Revenue Growth
  • QNCX N/A
  • IMUX N/A
  • 52 Week Low
  • QNCX $0.51
  • IMUX $0.92
  • 52 Week High
  • QNCX $2.45
  • IMUX $2.11
  • Technical
  • Relative Strength Index (RSI)
  • QNCX 36.52
  • IMUX 50.39
  • Support Level
  • QNCX $1.38
  • IMUX $0.92
  • Resistance Level
  • QNCX $1.49
  • IMUX $0.97
  • Average True Range (ATR)
  • QNCX 0.12
  • IMUX 0.06
  • MACD
  • QNCX -0.01
  • IMUX 0.01
  • Stochastic Oscillator
  • QNCX 7.32
  • IMUX 66.61

About QNCX Quince Therapeutics Inc.

Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Share on Social Networks: